Retatrutide is an investigational injectable medication currently undergoing clinical trials for the management of obesity and type 2 diabetes
An increase in the diagnosis of HFpEF was noted in both sexes [3, 4]
Expert Opin Investig Drugs 32(5):355359 Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Store it in cool, dry and dark places to avoid degradation
CD47 is primarily expressed on neurons and astrocytes, whereas its receptor SIRP is located on microglia